A prospective cohort study from Denmark investigated the link between maternal hormonal contraception use before — more than 3 months and within 3 months — and during pregnancy and risk of leukemia in their children.
Based on results of 2 prospective studies, the FDA approved the use of nilotinib in pediatric patients older than 1 year with newly diagnosed Ph+ CML-CP and those with TKI-intolerant or resistant disease.
A rare case of Langerhans cell histiocytosis (LCH) in a patient with idiopathic thrombocytopenic purpura (ITP) highlights the difficulty in diagnosing LCH.
The effectiveness of chemotherapy was enhanced by targeting survivin, a protein that inhibits apoptosis or cell death, according to preclinical research in cells and mouse models of retinoblastoma.
A new therapy might help treat a rare, high-risk cancer that begins development in the fetus or embryo, neuroblastoma, according to recent results from cell culture experiments.
Female survivors of childhood Hodgkin lymphoma (HL) who received chest radiation can reduce their risk of breast cancer through early screening.
Pediatric survivors of ALL treated only with chemotherapy remain at an increased risk for attention problems 2 years after treatment cessation.
Change in BMI does not reflect body composition of patients undergoing treatment for ALL, suggesting direct measures of body composition should be used to evaluate obesity in patients with leukemia.
A noninvasive, low-cost blood test was developed to help doctors diagnose some types of malignant childhood tumor. It could also enable treatment monitoring without exposing patients to repeated doses of radiation.
Researchers studying two generations of a family affected by pediatric ALL identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease.
